Navigation Links
ICON and MedAvante Sign Alliance Agreement

Partnership Aims To Enhance Precision and Reduce High Failure Rates in Central Nervous System Clinical Trials

DUBLIN and Hamilton, N.J., March 16 /PRNewswire-FirstCall/ -- ICON (Nasdaq: ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries and MedAvante, Inc. the leader in centralized psychiatric patient evaluation, today announced that they have signed an alliance agreement. This agreement will couple ICON's global reach and proven excellence in clinical trial management with MedAvante's innovative platform to centralize and calibrate the assessment of patients undergoing treatment in clinical trials. As a result, pharmaceutical and biotechnology trial sponsors will be able to reliably and precisely measure patients' response to therapies.

"MedAvante has developed a platform that addresses a major cause of clinical trial failure in Central Nervous System (CNS) development: variability in both clinical diagnosis of the disorder being studied and ongoing assessment of the severity of the patient's symptoms in a consistent and standardized fashion," says Dr. John Hubbard, President, ICON Clinical Research. "ICON is constantly striving to offer our pharmaceutical and biotechnology partners innovative clinical trial solutions to enhance the drug development process."

"ICON is a proven leader in the provision of high quality clinical research services," says Paul Gilbert, Chief Executive Officer of MedAvante. "This alliance extends our ability to offer our services across the industry and across the globe. Most importantly, however, is what this alliance provides to CNS drug developers: The ability on a larger scale to reduce the high rate of failed CNS clinical trials which the industry recognizes as unacceptable in terms of cost and lost time."

About ICON

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development -- from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 71 locations in 38 countries and has approximately 7,000 employees. Further information is available at

About MedAvante

MedAvante is a global provider of centralized expert psychological rating services to the pharmaceutical, biotechnology, and medical device industries. MedAvante is a pioneer in developing a solution for one of the most intractable problems in CNS clinical trials: the high rate of uninformative or failed studies. MedAvante applies unique methods to systematically remove potential sources of bias and variability from the assessment process. By centralizing assessments with expert, standardized, objective, clinical interviewers over MedAvante's 2-way, real-time, high quality video-conferencing, MedAvante makes subjective assessments of drug efficacy increasingly objective. As a result, sponsors can achieve increased study power and reduced trial-failure rates, enabling them to bring more effective CNS drugs to market sooner. MedAvante operates facilities in Hamilton, NJ; Los Angeles, CA; and Madison, WI. For more information about MedAvante, visit

Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
2. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
3. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
4. Lung Cancer Alliance Hails Announcement of New Erbitux(R) Data
5. Lung Cancer Alliance Commends NCCN on Screening Guidelines
6. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
7. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
8. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
9. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
10. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
11. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/25/2015)... 26, 2015  The total global healthcare industry is expected ... Latin America has the highest projected ... Japan ), is second with growth projected ... face increased healthcare expenditure. In 2013-2014, total government funded healthcare ... in 2008-2009 to 41.2% in 2013-2014. In real terms, out ...
Breaking Medicine Technology:
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... According ... at the recent 2015 American Dental Association meeting in Washington D.C. revolved around the ... protect a patient’s overall health. The talk stressed the link between periodontal disease (more ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has released ... Surviving Mesothelioma has just posted the findings on the website. Click here to ... cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with ... digital component is distributed nationally, through a vast social media strategy and across ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for ... of Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... CBD ... Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography ... CAAHEP accredited colleges, as only one of twelve colleges and universities in the state ...
Breaking Medicine News(10 mins):